iShares Edge MSCI USA Quality Factor UCITS ETF USD (Dist) (QDVBd)

Overview

DBV Technologies S.A. is a clinical-stage biopharmaceutical company established in 2002, with its headquarters located in Montrouge, France. The company is at the forefront of developing epicutaneous immunotherapy (EPIT) products, aimed at the research and development in the realm of allergies and immune-related diseases. It is dedicated to improving the lives of patients suffering from food allergies and other immunological diseases by leveraging its innovative Viaskin technology platform. This approach underscores DBV Technologies’ commitment to advancing healthcare through research, reflecting its status as a pioneer in the field of immunotherapy.

Products and Services

• Viaskin Peanut

Viaskin Peanut stands as a flagship product from DBV Technologies, crafted as an immunotherapy solution for peanut allergies. Having progressed through a Phase 3 clinical trial, Viaskin Peanut epitomizes the company’s dedication to offering innovative treatments. It employs the novel approach of epicutaneous delivery, wherein the therapy is administered through a patch that is placed on the skin. This method is designed to potentially desensitize individuals to peanut allergens, offering hope to many who are affected by this prevalent allergy.

• Viaskin Milk

Currently in a Phase 1/2 clinical trial, Viaskin Milk is DBV Technologies' venture into addressing cow's milk protein allergy and eosinophilic esophagitis, conditions predominantly associated with immunoglobulin E (IgE) mediation. This investigational product extends the use of the company’s patented epicutaneous immunotherapy platform, aiming to alleviate symptoms associated with milk allergies. By tackling such a common food allergy, Viaskin Milk signifies a major step forward in the global fight against allergic diseases.

• Vaccine Research Programs

The company is also venturing into earlier stage research, which includes the development of a vaccination for the respiratory syncytial virus, alongside potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. These programs signal DBV Technologies’ broader objective to harness and expand the applicability of its Viaskin technology beyond food allergies, targeting a wider array of immune-mediated conditions.

• MAG1C for CMPA Diagnosis

In collaboration with Nestlé Health Science, DBV Technologies is working on MAG1C, a novel atopy patch test designed for the diagnosis of non-IgE mediated cow's milk protein allergy (CMPA) in infants and toddlers. MAG1C represents an innovative diagnostic approach, potentially simplifying and improving the accuracy of diagnosing CMPA, which is often challenging. This partnership underscores the company's commitment to not only treating but also aiding in the accurate diagnosis of allergies.